Proteomics International Laboratories' (ASX:PIQ) subsidiary, OxiDx, received an intellectual property patent in China for its platform technology designed to precisely measure levels of oxidative stress, according to a Thursday filing with the Australian bourse.
The patent is valid until 2039. Aside from China, OxiDx's technology has intellectual protection in the US, Japan, Europe, and Australia. The company's application for a second-generation patent is pending in the US, Singapore, and India, the filing stated.
The medical technology company's shares were up over 1% in recent Thursday trade.